Literature DB >> 21436867

Clinical development directions in oncolytic viral therapy.

R M Eager1, J Nemunaitis.   

Abstract

Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy. Oncolytic viruses are replicative-competent viruses that are engineered to replicate selectively in cancer cells with specified oncogenic phenotypes. Multiple DNA and RNA viruses have been clinically tested in a variety of tumors. This review will provide a brief description of these novel anticancer biologics and will summarize the results of clinical investigation. To date oncolytic virotherapy has shown to be safe, and has generated clinical responses in tumors that are resistant to chemotherapy or radiotherapy. The major challenge for researchers is to maximize the efficacy of these viral therapeutics, and to establish stable systemic delivery mechanisms.
© 2011 Nature America, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21436867     DOI: 10.1038/cgt.2011.7

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  49 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

3.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

4.  Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.

Authors:  Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Terri A Shaffer; Corey Raffel; Eric M Jackson
Journal:  Neuro Oncol       Date:  2015-04-02       Impact factor: 12.300

5.  Giving oncolytic vaccinia virus more BiTE.

Authors:  Steven M Albelda; Steve H Thorne
Journal:  Mol Ther       Date:  2014-01       Impact factor: 11.454

6.  Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.

Authors:  Anniina Koski; Simona Bramante; Anja Kipar; Minna Oksanen; Juuso Juhila; Lotta Vassilev; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-07-09       Impact factor: 11.454

7.  Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Dennis H Kordish; Helene M Woyczesczyk; David Jeng; Karim Essani
Journal:  Virus Genes       Date:  2016-10-13       Impact factor: 2.332

8.  Retroviral replicating vectors in cancer.

Authors:  Christopher R Logg; Joan M Robbins; Douglas J Jolly; Harry E Gruber; Noriyuki Kasahara
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

9.  Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro.

Authors:  Li Li; Liang-Shun You; Li-Ping Mao; Shen-He Jin; Xiao-Hui Chen; Wen-Bin Qian
Journal:  Acta Pharmacol Sin       Date:  2017-09-14       Impact factor: 6.150

Review 10.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.